Detalles de la búsqueda
1.
Corrigendum: Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells.
Nat Immunol
; 17(10): 1235, 2016 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27648550
2.
B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen.
Nat Immunol
; 13(2): 170-80, 2011 Dec 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-22197976
3.
The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88.
Nat Immunol
; 11(9): 836-45, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20676093
4.
Identification of EWSR1 rearrangements in patients with immature hematopoietic neoplasms: A case series and review of literature.
Ann Diagn Pathol
; 58: 151942, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35344861
5.
HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits.
Nat Immunol
; 10(9): 1008-17, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19648924
6.
Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils.
Nat Immunol
; 10(8): 889-98, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19561614
7.
Core Stability Exercises in Addition to Usual Care Physiotherapy Improve Stability and Balance After Stroke: A Systematic Review and Meta-analysis.
Arch Phys Med Rehabil
; 102(4): 762-775, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33239203
8.
Anakinra-associated renal amyloidosis.
Kidney Int
; 105(2): 395-396, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38245224
9.
De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity.
Mod Pathol
; 31(5): 705-717, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29327715
10.
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood
; 128(11): 1458-64, 2016 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27458003
11.
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Blood
; 128(26): 3083-3100, 2016 12 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-27760757
12.
CD30 Expression Is Rare in Myeloid Leukemia Cutis: A Study of 55 Cases and Implications for Routine Diagnostic Algorithms.
Am J Dermatopathol
; 39(5): 351-357, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27893466
13.
Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Mod Pathol
; 28(12): 1555-73, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26541272
14.
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.
Mod Pathol
; 28(10): 1297-314, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26248897
15.
Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.
Mod Pathol
; 28(9): 1202-13, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26111978
16.
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Blood
; 122(15): 2630-40, 2013 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23982177
17.
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Blood
; 121(14): 2715-24, 2013 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-23343832
18.
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Blood
; 121(20): 4021-31; quiz 4250, 2013 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-23449635
19.
Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP.
Am J Hematol
; 95(2): E31-E34, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31705546
20.
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Blood
; 120(19): 3986-96, 2012 Nov 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-22955915